Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial.

One of the main causes of acute respiratory distress syndrome in coronavirus disease 2019 (COVID-19) is cytokine storm, although the exact cause is still unknown. Umbilical cord mesenchymal stromal cells (UC-MSCs) influence proinflammatory T-helper 2 (Th ) cells to shift to an anti-inflammatory agent. To investigate efficacy of UC-MSC administration as adjuvant therapy in critically ill patients with COVID-19, we conducted a double-blind, multicentered, randomized controlled trial at four COVID-19 referral hospitals in Jakarta, Indonesia.

Temporary storage solution for adipose derived mesenchymal stem cells.

Background: We have developed a simple lipoaspirate washing method using a coffee filter to eliminate liposuction noxious material before isolating adipose tissue derived mesenchymal stem cells (AT-MSCs), and used them in clinical trials. Before administration to patients, MSCs are usually suspended in physiologic saline. However, MSCs only survive for a limited time in physiologic saline.